Detailed Coverage

Aurobindo Pharma Subsidiary Secures Brazil GMP Approval

CuraTeQ Biologics Private Limited, a wholly-owned subsidiary of Aurobindo Pharma, has received Good Manufacturing Practice (GMP) approval from the National Health Surveillance Agency of Brazil (ANVISA). The approval pertains to its biosimilars manufacturing facility located in Hyderabad.

What just happened

The ANVISA GMP approval was granted following an inspection of the Hyderabad facility conducted between May 11 and May 15, 2026. The inspection covered the manufacturing of biosimilar drug substances (mammalian and microbial), filling, packaging, labelling, and quality control laboratories.

Why this matters

This regulatory clearance is a significant step for Aurobindo Pharma's biologics division, enhancing its capacity to supply biosimilar products to Brazil and the wider Latin American markets. The facility already holds certifications from the European Medicines Agency (EMA) and the World Health Organization (WHO).

Reader Takeaway: GMP approval unlocks Brazil market access; validates global quality standards.

The backstory

CuraTeQ Biologics operates a facility that manufactures biosimilars. The company is focused on expanding its biologics business geographically, and approvals from major regulatory bodies are key to this strategy.

What changes now

With ANVISA approval, CuraTeQ Biologics can now commercialize its biosimilar products in Brazil. This is expected to contribute to the company's revenue growth in the Latin American region.

Risks to watch

While this is a positive development, investors will need to monitor the actual commercial uptake and revenue generation from the Brazilian market. Competition in the biosimilars space also remains a factor.

Peer comparison

Many Indian pharmaceutical companies are expanding their biologics and biosimilars portfolios. Aurobindo's ability to secure approvals from multiple stringent regulatory authorities like EMA, WHO, and now ANVISA positions it competitively.

Context metrics

The inspection period was May 11 to May 15, 2026.

What to track next

Investors should watch for announcements regarding product launches in Brazil and the subsequent sales performance of CuraTeQ's biosimilars in the Latin American market.